Identification and Functional Analysis of Hub Genes in Cell Cycle Pathway Linked to the Development of Lung Cancer with Non-Small Cells

Meixi Chen; Jiajing Pan; Guanyang Wang

doi:10.54097/pz3fvz54

Authors

Meixi Chen
Jiajing Pan
Guanyang Wang

DOI:

https://doi.org/10.54097/pz3fvz54

Keywords:

non-small cell lung cancer; Cell cycle; bioinformatics analysis; KRAS mutation; EGFR mutation; Gene Copy Number Alteration.

Abstract

Non-small cell lung cancer (NSCLC) is the most prevalent cause of cancer-related fatalities. We combined different gene expression datasets to screen out eight hub genes (CDC6, PLK1, BUB1B, CHEK1, TTK, CDC20, CCNB2, and PTTG1) associated with the Cell cycle pathway, which also showed significant poor prognosis and late upregulation of LUAD in NSCLC. KRAS and EGFR are the star molecules in lung cancer. KRAS causes overexpression of hub genes through up-regulation of the cell cycle pathway, and the up-regulation of hub genes in NSCLC can be confirmed at amounts of mRNA and proteins. Hub genes have a certain correlation with EGFR, and upregulation of the cell cycle pathway may cause resistance in NSCLC caused by EGFR mutations. The emergence of this resistance may be related to the change of Gene copy number alteration (CAN) and co-occurrence of BUB1B and CCNB2, PLK1 and TTK, CHEK1 and TTK. These cell cycle subtype genes provide a new perspective for treating patients with NSCLC, and the specific mechanism of hub genes can be further studied.

Downloads

Download data is not yet available.

References

SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer Statistics, 2021. CA: a cancer journal for clinicians, 2021, 71(1): 7-33.

ARBOUR K C, RIELY G J. Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review. Jama, 2019, 322(8): 764-74.

CHEN Z, FILLMORE C M, HAMMERMAN P S, et al. Non-small-cell lung cancers: a heterogeneous set of diseases. Nature reviews Cancer, 2014, 14(8): 535-46.

WANG M, HERBST R S, BOSHOFF C. Toward personalized treatment approaches for non-small-cell lung cancer. Nature medicine, 2021, 27(8): 1345-56.

RICCIUTI B, ALESSI J V, ELKRIEF A, et al. Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS(G12D)-mutated non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2022, 33(10): 1029-40.

MILLER M, HANNA N. Advances in systemic therapy for non-small cell lung cancer. BMJ (Clinical research ed), 2021, 375: n2363.

TANG Z, KANG B, LI C, et al. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic acids research, 2019, 47(W1): W556-w60.

DAI Y, WANG L, TANG J, et al. Activation of anaphase-promoting complex by p53 induces a state of dormancy in cancer cells against chemotherapeutic stress. Oncotarget, 2016, 7(18): 25478-92.

TANG Z, BHARADWAJ R, LI B, et al. Mad2-Independent inhibition of APCCdc20 by the mitotic checkpoint protein BubR1. Developmental cell, 2001, 1(2): 227-37.

WANG Y, SCHMID-BINDERT G, ZHOU C. Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians. Therapeutic advances in medical oncology, 2012, 4(1): 19-29.